What is BioNexus Gene Lab Cash, Cash Equivalents, Marketable Securities?
BioNexus Gene Lab's quarterly cash, cash equivalents, marketable securities
declined
from Sep. 2023 ($6.15 Mil) to Dec. 2023 ($5.93 Mil) but then
stayed the same
from Dec. 2023 ($5.93 Mil) to Mar. 2024 ($5.83 Mil).
BioNexus Gene Lab's annual cash, cash equivalents, marketable securities
declined
from Dec. 2021 ($2.12 Mil) to Dec. 2022 ($2.12 Mil) but then
increased
from Dec. 2022 ($2.12 Mil) to Dec. 2023 ($5.93 Mil).
BioNexus Gene Lab Cash, Cash Equivalents, Marketable Securities Historical Data
The historical data trend for BioNexus Gene Lab's Cash, Cash Equivalents, Marketable Securities can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.
Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.
Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.
A high number means either:
1) The company has competitive advantage generating lots of cash
2) Just sold a business or bonds (not necessarily good)
A low stockpile of cash usually means poor to mediocre economics.
There are 3 ways to create large cash reserve.
1) Sell new bonds or equity to public
2) Sell business or asset
3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)
When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.
Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.
Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.
BioNexus Gene Lab Cash, Cash Equivalents, Marketable Securities Related Terms
Thank you for viewing the detailed overview of BioNexus Gene Lab's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.
BioNexus Gene Lab (BioNexus Gene Lab) Business Description
BioNexus Gene Lab Corp is an emerging molecular diagnostics company focused on the application of functional genomics to enable early diagnosis and personalized health management. It focuses on developing and marketing safe, effective, and non-invasive blood tests for the early detection of diseases. The company's non-invasive blood tests analyze changes in ribonucleic acid (or RNA) to detect the potentiality of 11 different diseases. These diseases include eight cancers (nasopharyngeal, lung, liver, stomach, breast, cervical, prostate, and colon), two bowel diseases (colitis and Crohn), and osteoarthritis.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BGLC has been successfully added to your 